Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To assess safety of baricitinib in Japanese patients with rheumatoid arthritis (RA) in real-world clinical practice.
Methods: This all-case postmarketing surveillance study included patients initiating baricitinib for RA from September 2017 to April 2019. Treatment duration was recorded. Safety data were collected for up to 3 years from initiation (up to 4 weeks postdiscontinuation in discontinuing patients).
Results: Safety analyses included 4720 patients; 2580 (54.7%) were ≥65 years old. Baricitinib persistence rate was 45.4% (3-year Kaplan-Meier analysis); the most common discontinuation reason was insufficient effectiveness (n = 1005, 21.3%). Serious adverse events occurred in 600 patients [incidence rate (IR) 10.42/100 patient-years (PY); 95% confidence interval, 9.76-11.09]. There were 39 deaths [IR 0.43 (0.30-0.57)/100 PY]. Adverse events of special interest IRs per 100 PY were herpes zoster 4.68 (4.22-5.14), serious infection 3.05 (2.68-3.41), malignancy 1.09 (0.87-1.30), major adverse cardiovascular events 0.35 (0.23-0.48), and venous thromboembolism 0.25 (0.15-0.36). IRs did not increase with prolonged exposure.
Conclusions: No new safety concerns were identified during this 3-year postmarketing surveillance study of baricitinib in Japanese patients with RA. Patients and clinicians should be cognizant of herpes zoster and other serious infection risks during baricitinib treatment, especially in the first 6 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/mr/roae064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study.
J Dermatolog Treat
December 2025
Department of Dermatology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Objectives: Baricitinib showed efficacy for alopecia areata (AA) in clinical trials, with real-world data supporting its short-term effectiveness. However, long-term data are limited. We assessed the effectiveness and safety of baricitinib in AA patients over one year and explored predictive factors.
View Article and Find Full Text PDFA pilot transcriptomic study of a novel multitargeted BRT regimen for anti-MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy.
Front Immunol
August 2025
Division of Rheumatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Background: Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM) is associated with severe outcomes, primarily due to rapidly progressive interstitial lung disease (RP-ILD), which is often refractory to standard therapies such as calcineurin inhibitors (e.g., tacrolimus) combined with cyclophosphamide (TC-Tx).
View Article and Find Full Text PDFComparison of tocilizumab and corticosteroid treatment with baricitinib and corticosteroid treatment in severely and critically ill patients with coronavirus disease 2019.
Respir Investig
September 2025
Division of Infectious Diseases and Infection Control, Department of Social and Community Medicine, Graduate School of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyagino-ku, Sendai City, Miyagi, 983-8536, Japan; Division of Infectious Diseases, Tohoku Medical and Pharm
Background: Several guidelines recommend that systemic therapies involving tocilizumab, baricitinib, and corticosteroids are crucial in treating severely and critically ill patients with coronavirus disease 2019 (COVID-19). However, the efficacy of the tocilizumab and corticosteroid combination compared with the baricitinib and corticosteroid combination in severely and critically ill hospitalized patients with COVID-19 remains unclear.
Methods: We analyzed severely and critically ill hospitalized patients with COVID-19 aged ≥18 years between 1 January 2020 and 31 March 2023 using a Japanese inpatient database.
Recommendations for the treatment of juvenile idiopathic arthritis with oligoarthritis or polyarthritis from the 2024 update of the Japan College of Rheumatology Clinical Practice Guidelines for the management of rheumatoid arthritis including juvenile idiopathic arthritis with oligoarthritis or polyarthritis - secondary publication.
Mod Rheumatol
September 2025
Division of Rheumatology, Department of Internal Medicine, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Objectives: To conduct systematic reviews (SRs) and develop clinical practice guidelines (CPGs) for managing juvenile idiopathic arthritis (JIA) with oligoarthritis or polyarthritis.
Methods: The Grading of Recommendations, Assessment, Development, and Evaluation methodology was employed to carry out SRs and formulate the CPGs. An expert panel, including patients, paediatric and nonpaediatric rheumatologists, guideline specialists, and patient representatives, used the Delphi method to discuss and agree on the recommendations.
Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis.
Int J Rheum Dis
May 2025
Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Aim: To compare the clinical effectiveness of baricitinib and filgotinib in the treatment of rheumatoid arthritis (RA).
Methods: This retrospective study included 101 and 103 consecutive patients treated with baricitinib and filgotinib, respectively, between 2020 and 2023. Drug retention was analyzed using Kaplan-Meier curves, with the log-rank test for between-group comparisons.